Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma.

Abstract

INTRODUCTION:

Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was recently approved for relapsed or refractory follicular lymphoma following progression on two or more lines of therapy including an anti-CD20 monoclonal antibody with an alkylating agent, providing a therapeutic breakthrough in a subset of indolent non-Hodgkin lymphoma associated with poor clinical outcomes.

AREAS COVERED:

In this article, we outline the drug profile of axicabtagene ciloleucel in comparison to currently approved agents and other CAR T-cell and T-cell redirecting therapies under investigation for the treatment of relapsed or refractory follicular lymphoma. We also review the efficacy, safety, and pharmacokinetic data from the ZUMA-5 phase II trial, which forms the basis of the recent approval of axicabtagene ciloleucel.

EXPERT OPINION:

Axicabtagene ciloleucel is the first cellular therapy approved for relapsed or refractory follicular lymphoma, demonstrating high rates of durable responses and a manageable toxicity profile in heavily pre-treated patients.

• Authors: Jared A Cohen, Armin Ghobadi
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 22 Issue 9 Pg. 903-914 (09 2022) ISSN: 1744-8328 [Electronic] England
• PMID: 35786133 (Publication Type: Journal Article)

Chemical References

• Antigens, CD19
• Biological Products
• axicabtagene ciloleucel

Topics

• Antigens, CD19 (adverse effects)
• Biological Products (adverse effects)
• Drug Approval
• Humans
• Immunotherapy, Adoptive (adverse effects)
• Lymphoma, Follicular (drug therapy)
• Neoplasm Recurrence, Local (drug therapy)